Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies that enhance regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases. Its pipeline centers on COYA 301, COYA 302, COYA 303, and exosome-based programs, with a current focus on advancing COYA 302 in ALS and FTD through clinical studies and partnering arrangements.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueDrug candidates designed to enhance regulatory T cell function in disease.
Combination biologic program being advanced in ALS and FTD clinical studies.
Backbone and follow-on programs intended for combination use and new indications.
Preclinical work on Treg-derived exosomes as a potential therapeutic modality.
Customers
Coya does not yet sell approved products; its near-term counterparties are clinical investigators, research collaborators, and licensing partners rather than end patients. If approved, its therapies would be used by physicians treating ALS, FTD, Alzheimer’s disease, Parkinson’s disease, autoimmune disease, and potentially metabolic disease patients. The company also relies on third-party payors and reimbursement systems for eventual commercialization.
Patients with ALS and other neurodegenerative diseases enrolled to test safety and efficacy of COYA 302.
Dr. Reddy's holds commercialization rights in defined territories and supports development/commercialization of COYA 302.
Academic and hospital collaborators that support preclinical validation and sponsored research on exosomes and Tregs.
Specialists and reimbursement bodies that would determine adoption and access if products are approved.
Strategy
Coya’s strategy is to build a Treg-focused pipeline across neurodegenerative and autoimmune diseases, with COYA 302 as the lead clinical asset. It is also trying to extend the platform through COYA 301, COYA 303, and exosome programs while using partnerships and licensing to reduce development burden and broaden reach.
This is the company’s principal near-term value driver and the most advanced program.
Broader indications could increase the commercial opportunity for the same platform.
These programs are intended to create a modular pipeline and support future combinations.
The company is pre-revenue and needs external funding to extend runway and de-risk development.
Geography
Coya is headquartered in the United States and conducts its core development work there. Its disclosed commercial rights for COYA 302 span the U.S., Canada, the European Union, the United Kingdom, and other ex-U.S. territories through licensing arrangements, while Japan, Mexico, and South America are also referenced in its territorial structure. Because the company is pre-commercial, geography mainly affects where trials, licensing rights, and future reimbursement pathways are concentrated.
Risks
Coya is a clinical-stage company with no approved products, so its value depends on successful trial outcomes, regulatory approvals, and eventual reimbursement. It also faces financing risk because it has ongoing losses and will need additional capital, plus execution risk from reliance on third-party licensors, manufacturers, and collaborators.
- Clinical development failureImpact: CriticalLikelihood: Medium
COYA 302 and other programs are investigational and may not show efficacy or safety in later studies.
Exposure: ALSTARS Phase 2 and future neurodegenerative indications
- Dependence on licensed intellectual propertyImpact: HighLikelihood: Medium
Key programs rely on third-party licenses; termination or unfavorable terms could impair the pipeline.
Exposure - Financing and going-concern riskImpact: High
The company has recurring losses and will need substantial additional capital to continue development.
Exposure - Manufacturing and supply-chain dependenceImpact: MediumLikelihood: Medium
Programs depend on specialized vendors and equipment for cell therapy and exosome work.
Exposure - Reimbursement and market-access uncertaintyImpact: MediumLikelihood: Medium
Even if approved, uptake will depend on coverage, pricing, and payor acceptance.
Exposure: Physician-administered specialty therapies in the U.S. and abroad
Accounting
Judgemental itemsRevenue is derived from the DRL Development Agreement and includes license and service components recognized over time or upon triggering events.
Impact: Can cause lumpy quarterly revenue and margin volatility
Management estimates unpaid clinical, preclinical, and vendor costs at period end.
Impact: Affects operating expenses and current liabilities
Fair value depends on assumptions such as volatility and discount for lack of marketability.
Impact: Can materially affect G&A and R&D expense
Persistent losses and funding needs require management to assess liquidity and disclosure.
Impact: Important for evaluating runway and capital risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
BioVie Inc
BIVIW · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Taysha Gene Therapies, Inc.
TSHA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026